Nicholas Mitrokostas

Nicholas Mitrokostas

Goodwin

Contact
View Bio
RSS

Latest Posts › Biogen Idec

Share:

Biogen/Samsung Approval of BYOOVIZ™

Samsung Bioepis, Co. Ltd. and Biogen Inc. announced yesterday that their biosimilar product BYOOVIZ™ (ranibizumab-nuna) was approved by FDA.  BYOOVIZ™ is a biosimilar to LUCENTIS®, which is indicated for the treatment of...more

9/24/2021  /  Biogen Idec , Biosimilars , FDA Approval , Food and Drug Administration (FDA) , IP License , Pharmaceutical Industry , Prescription Drugs , Samsung Bioepis
1 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide